135 related articles for article (PubMed ID: 25318697)
21. What are the predictive factors in the risk and severity of chemotherapy-induced gastrointestinal toxicity?
Gibson RJ; Bowen JM; Coller JK
Future Oncol; 2015; 11(17):2367-70. PubMed ID: 26270862
[No Abstract] [Full Text] [Related]
22. Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors.
Denlinger CS; Blanchard R; Xu L; Bernaards C; Litwin S; Spittle C; Berg DJ; McLaughlin S; Redlinger M; Dorr A; Hambleton J; Holden S; Kearns A; Kenkare-Mitra S; Lum B; Meropol NJ; O'Dwyer PJ
Cancer Chemother Pharmacol; 2009 Dec; 65(1):97-105. PubMed ID: 19415281
[TBL] [Abstract][Full Text] [Related]
23. Effects of budesonide on toll-like receptor expression in alveolar macrophages from smokers with and without COPD.
Ji J; von Schéele I; Billing B; Dahlén B; Lantz AS; Larsson K; Palmberg L
Int J Chron Obstruct Pulmon Dis; 2016; 11():1035-43. PubMed ID: 27274225
[TBL] [Abstract][Full Text] [Related]
24. Combinations of polymorphisms in genes involved in the 5-Fluorouracil metabolism pathway are associated with gastrointestinal toxicity in chemotherapy-treated colorectal cancer patients.
Afzal S; Gusella M; Vainer B; Vogel UB; Andersen JT; Broedbaek K; Petersen M; Jimenez-Solem E; Bertolaso L; Barile C; Padrini R; Pasini F; Jensen SA; Poulsen HE
Clin Cancer Res; 2011 Jun; 17(11):3822-9. PubMed ID: 21471424
[TBL] [Abstract][Full Text] [Related]
25. HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.
Garziera M; Virdone S; De Mattia E; Scarabel L; Cecchin E; Polesel J; D'Andrea M; Pella N; Buonadonna A; Favaretto A; Toffoli G
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28653974
[TBL] [Abstract][Full Text] [Related]
26. Gastro-intestinal toxicity of chemotherapeutics in colorectal cancer: the role of inflammation.
Lee CS; Ryan EJ; Doherty GA
World J Gastroenterol; 2014 Apr; 20(14):3751-61. PubMed ID: 24744571
[TBL] [Abstract][Full Text] [Related]
27. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract][Full Text] [Related]
28. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
Pusztai L; Mendoza TR; Reuben JM; Martinez MM; Willey JS; Lara J; Syed A; Fritsche HA; Bruera E; Booser D; Valero V; Arun B; Ibrahim N; Rivera E; Royce M; Cleeland CS; Hortobagyi GN
Cytokine; 2004 Feb; 25(3):94-102. PubMed ID: 14698135
[TBL] [Abstract][Full Text] [Related]
29. Standard fluoropyrimidine dosages in chemoradiation therapy result in an increased risk of severe toxicity in DPYD variant allele carriers.
Lunenburg CATC; Henricks LM; Dreussi E; Peters FP; Fiocco M; Meulendijks D; Toffoli G; Guchelaar HJ; Swen JJ; Cecchin E; Schellens JHM; Gelderblom H
Eur J Cancer; 2018 Nov; 104():210-218. PubMed ID: 30361102
[TBL] [Abstract][Full Text] [Related]
30. Plasma diamine oxidase activity is a useful biomarker for evaluating gastrointestinal tract toxicities during chemotherapy with oral fluorouracil anti-cancer drugs in patients with gastric cancer.
Namikawa T; Fukudome I; Kitagawa H; Okabayashi T; Kobayashi M; Hanazaki K
Oncology; 2012; 82(3):147-52. PubMed ID: 22433290
[TBL] [Abstract][Full Text] [Related]
31. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
Ozdemir NY; Abali H; Oksüzoğlu B; Budakoglu B; Uncu D; Güler T; Odabaşi H; Zengin N
Med Oncol; 2010 Sep; 27(3):680-4. PubMed ID: 19633962
[TBL] [Abstract][Full Text] [Related]
33. ABCB1 and ABCC2 genetic polymorphism as risk factors for neutropenia in esophageal cancer patients treated with docetaxel, cisplatin, and 5-fluorouracil chemotherapy.
Nomura H; Tsuji D; Demachi K; Mochizuki N; Matsuzawa H; Yano T; Daiko H; Fujii S; Kojima T; Itoh K; Kawasaki T
Cancer Chemother Pharmacol; 2020 Aug; 86(2):315-324. PubMed ID: 32748110
[TBL] [Abstract][Full Text] [Related]
34. Dosimetric parameters predictive of acute gastrointestinal toxicity in patients with anal carcinoma treated with concurrent chemotherapy and intensity-modulated radiation therapy.
DeFoe SG; Kabolizadeh P; Heron DE; Beriwal S
Oncology; 2013; 85(1):1-7. PubMed ID: 23736101
[TBL] [Abstract][Full Text] [Related]
35. The influence of gender on human innate immunity.
Imahara SD; Jelacic S; Junker CE; O'Keefe GE
Surgery; 2005 Aug; 138(2):275-82. PubMed ID: 16153437
[TBL] [Abstract][Full Text] [Related]
36. L-Carnosine protects against Oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: A perspective on targeting Nrf-2 and NF-κB pathways.
Yehia R; Saleh S; El Abhar H; Saad AS; Schaalan M
Toxicol Appl Pharmacol; 2019 Feb; 365():41-50. PubMed ID: 30592963
[TBL] [Abstract][Full Text] [Related]
37. Gastrointestinal nematode infection is associated with variation in innate immune responsiveness.
Jackson JA; Turner JD; Kamal M; Wright V; Bickle Q; Else KJ; Ramsan M; Bradley JE
Microbes Infect; 2006 Feb; 8(2):487-92. PubMed ID: 16293435
[TBL] [Abstract][Full Text] [Related]
38. Taxane-based regimens as a risk factor for chemotherapy-induced amenorrhea.
Najafi S; Djavid GE; Mehrdad N; Rajaii E; Alavi N; Olfatbakhsh A; Najafi M; Bahrami A; Heidari K
Menopause; 2011 Feb; 18(2):208-12. PubMed ID: 21037487
[TBL] [Abstract][Full Text] [Related]
39. Relation between cytokine promoter gene polymorphism and toxicity of 5-fluorouracil plus cisplatin chemotherapy.
Sakamoto K; Oka M; Yoshino S; Hazama S; Abe T; Okayama N; Hinoda Y
Oncol Rep; 2006 Aug; 16(2):381-7. PubMed ID: 16820919
[TBL] [Abstract][Full Text] [Related]
40. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
